玻璃体腔内抗血管内皮生长因子治疗病理性近视继发脉络膜新生血管：6年随访结果

INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: SIX YEARS OUTCOME.

作者信息

Ruiz-Moreno Jose M, Montero Javier A, Araiz Javier, Arias Luis, García-Layana Alfredo, Carneiro Angela, Figueroa Marta S, Silva Rufino

机构信息

*Department of Ophthalmology, Castilla La Mancha University, Albacete and Baviera European Institute of Retina, Alicante, Spain; †Pío del Río Hortega University Hospital, Department of Ophthalmology, Valladolid and Oftalvist, Retina Unit, Madrid, Spain; ‡University of the Basque Country (Surgical-Clinical Institute of Ophthalmology) and San Eloy Hospital, Bilbao, Spain; §Bellvitge University Hospital, Department of Ophthalmology, Barcelona, Spain; ¶Navarra University Hospital, Department of Ophthalmology, Pamplona, Spain; **Department of Sense Organs of Faculty of Medicine of University of Porto and Department of Ophthalmology of Hospital of São João, Porto, Portugal; and ††Faculty of Medicine University of Coimbra (FMUC), Coimbra Hospital and University Centre (CHUC) and Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal.

出版信息

Retina. 2015 Dec;35(12):2450-6. doi: 10.1097/IAE.0000000000000632.

DOI:10.1097/IAE.0000000000000632

PMID:26049616

Abstract

PURPOSE

To report the visual outcome after 6-year follow-up in highly myopic eyes with choroidal neovascularization treated with anti-vascular endothelial growth factor drugs.

METHODS

Retrospective, nonrandomized, multicenter, consecutive, and interventional case series.

RESULTS

Seventy-eight patients were treated with intravitreal bevacizumab and 19 with ranibizumab. Mean age of the patients was 56.5 years (SD, 13.3). The average number of letters read was 56.7 (SD, 19.0) at baseline; 65.7 (SD, 18.4) at 12 months; 63.6 (SD, 20.6) at 24 months; 62.4 (SD, 21.4) at 36 months; 60.6 (SD, 22.0) at 48 months; 58.9 (SD, 22.9) at 60 months, and 58.4 (SD, 22.7) at 72 months (P < 0.01, between initial vs. 12, 24, and 36 months; P = 0.07, 0.3, and 0.5 between initial vs. 48, 60, and 72 months, respectively; Student's t-test paired data). The mean total number of intravitreal injections was 3.3 (SD, 2.3; range, 1-9).

CONCLUSION

Bevacizumab and ranibizumab are effective therapies and show similar clinical effects in myopic eyes with choroidal neovascularization. Visual acuity gain is maintained at a 3-year follow-up. The improvement is no longer statistically significant at Years 4, 5, and 6.

摘要

目的

报告抗血管内皮生长因子药物治疗高度近视性脉络膜新生血管6年随访后的视力结果。

方法

回顾性、非随机、多中心、连续干预病例系列。

结果

78例患者接受玻璃体内注射贝伐单抗治疗，19例接受雷珠单抗治疗。患者的平均年龄为56.5岁（标准差13.3）。基线时平均阅读字母数为56.7（标准差19.0）；12个月时为65.7（标准差18.4）；24个月时为63.6（标准差20.6）；36个月时为62.4（标准差21.4）；48个月时为60.6（标准差22.0）；60个月时为58.9（标准差22.9）；72个月时为58.4（标准差22.7）（初始与12、24和36个月之间，P<0.01；初始与48、60和72个月之间，P分别为0.07、0.3和0.5；配对数据的学生t检验）。玻璃体内注射的平均总数为3.3（标准差2.3；范围1 - 9）。